Your browser doesn't support javascript.
loading
Benchmarking Time-to-Treatment Initiation in Sarcoma Care Using Real-World-Time Data.
Schärer, Markus; Heesen, Philip; Bode-Lesniewska, Beata; Studer, Gabriela; Fuchs, Bruno.
Afiliação
  • Schärer M; Sarcoma Service, Department of Orthopaedics and Trauma, University Teaching Hospital LUKS, 6000 Lucerne, Switzerland.
  • Heesen P; Health Sciences and Medical Faculty, University of Lucerne, 6001 Lucerne, Switzerland.
  • Bode-Lesniewska B; Sarcoma Service, Department of Orthopaedics and Trauma, Kantonsspital Winterthur, 8400 Winterthur, Switzerland.
  • Studer G; Sarcoma Service, University Hospital USZ, University of Zurich, 8000 Zurich, Switzerland.
  • Fuchs B; Pathologie Institut Enge, University of Zurich, 8000 Zurich, Switzerland.
Cancers (Basel) ; 15(24)2023 Dec 15.
Article em En | MEDLINE | ID: mdl-38136394
ABSTRACT
Benchmarking is a fundamental tool for enhancing quality within a patient-centered healthcare framework. This study presents an analysis of time-to-treatment initiation (TTI) for sarcoma patients, utilizing a database encompassing 266 cases from the Swiss Sarcoma Network. Our findings indicate a median TTI of 30 days across the cohort, with bone sarcomas and deep soft tissue sarcomas demonstrating a shorter median TTI of 28 days, followed by superficial soft tissue sarcomas at 42 days. The data reveal that the use of real-world-time data (RWTD) may account for a longer TTI observed, as it offers more comprehensive capture of patient journeys, unlike conventional datasets. Notably, variability in TTI was observed between different treatment institutions, which underscores the need for standardized processes across centers. We advocate for a selective referral system to specialized centers to prevent capacity overload and ensure timely treatment initiation. Our analysis also identified significant delays in TTI for unplanned 'whoops'-resections, highlighting the importance of early specialist referral in optimizing treatment timelines. This study emphasizes the potential benefits of a streamlined, data-informed approach to sarcoma care. However, further research is required to establish the direct impact of integrated care models on TTI and patient outcomes in the context of sarcoma treatment.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça